



## AGENDA

Thursday, December 17, 2015, Heart House

7:30am	<b>BREAKFAST AVAILABLE</b>
8:00am	<b>Introduction to Heart House</b> <i>Shal Jacobovitz, ACC, Chief Executive Officer</i>
8:05am	<b>Opening Remarks and Introductions</b> <i>Laura Mauri, MD, MSc, FACC, Chair and Moderator</i>
8:20am	<b>Keynote Address: Overview of Management of Valvular Heart Disease</b> <i>Patrick T. O’Gara, MD, MACC</i>
8:40am	<b>Session 1: Overview of the Current Guidelines and Challenges in the Assessment and Management of AS and MR</b> <ul style="list-style-type: none"><li>• <b>Challenges in diagnosing and assessing severity of AS and MR</b> <i>Catherine M. Otto, MD, FACC (15 minutes)</i></li><li>• <b>Evolving guidelines: Rapid updates and adoption into practice</b> <i>Rick A. Nishimura, MD, MACC (15 minutes)</i></li><li>• Interactive Table Discussion (55 minutes)</li><li>• Report Back to Full Group (25 minutes)</li></ul>
10:30am	<b>BREAK</b>
10:45am	<b>Session 2: Emerging Transcatheter Therapies in AS (TAVR)</b> <ul style="list-style-type: none"><li>• <b>Risk stratification for TAVR – Is my patient too sick, old, or frail?</b> <i>Karen P. Alexander, MD, FACC (10 minutes)</i></li><li>• <b>Considering SAVR in the TAVR era – Surgical implications of TAVR</b> <i>Vinod H. Thourani, MD, FACC, FACS (10 minutes)</i></li><li>• Interactive Table Discussion (60 minutes)</li><li>• Report Back to Full Group (25 minutes)</li></ul>
12:30pm	<b>LUNCH</b>
1:15pm	<b>Session 3: Future Directions and Improving AS Care</b> <ul style="list-style-type: none"><li>• <b>How do we prepare for the expansion of TAVR to lower risk populations?</b> <i>Dharam J. Kumbhani, MD, SM, FACC (10 minutes)</i></li><li>• <b>Evolution of the multidisciplinary heart valve team – where are we going?</b> <i>Joseph E. Bavaria, MD (10 minutes)</i></li><li>• <b>Assessing LV health in the management and treatment of AS</b> <i>Brian R. Lindman, MD, MSCI, FACC (10 minutes)</i></li><li>• Interactive Table Discussion (55 minutes)</li><li>• Report Back to Full Group (25 minutes)</li></ul>
3:05pm	<b>BREAK</b>
3:20pm	<b>Session 4: Engagement of Patients and Trainees in the Management of Valvular Heart Disease</b> <ul style="list-style-type: none"><li>• <b>Balancing treatment options for AS and MR: A patient’s perspective</b> <i>Christina M. Vassileva, MD, FACS, FACC; Donnette Smith, Kathleen Reid (10 minutes)</i></li><li>• <b>Shared decision-making and implementation</b> <i>Megan Coylewright, MD, MPH (10 minutes)</i></li><li>• <b>Education and training: How and who do we need to train for the future of transcatheter valve treatment</b> <i>Sammy Elmariah, MD, MPH, FACC (10 minutes)</i></li><li>• Interactive Table Discussion (45 minutes)</li><li>• Report Back to Full Group (25 minutes)</li></ul>
5:00pm	<b>Recap of the Day</b>
5:15pm	<b>RECEPTION</b>



Friday, December 18, 2015, Heart House

7:30am	<b>BREAKFAST AVAILABLE</b>
8:00am	<b>Session 5: Managing MR and the Incorporation of Transcatheter Mitral Valve Repair</b> <ul style="list-style-type: none"><li>• <b>Transcatheter mitral valve repair or medical therapy for the inoperable patient?</b> <i>Randolph P. Martin, M.D., FACC, FASE, FESC (15 minutes)</i></li><li>• <b>Advances in the management of MR</b> <i>Michael J. Mack, MD, FACC (15 minutes)</i></li><li>• Interactive Table Discussion (60 minutes)</li><li>• Report Back to Full Group (30 minutes)</li></ul>
10:00am	<b>BREAK</b>
10:15am	<b>Session 6: Future Directions and Improving MR Care</b> <ul style="list-style-type: none"><li>• <b>Primary/Secondary, Functional/Degenerative/Ischemic – How do we simplify MR care?</b> <i>Robert O. Bonow, MD, MACC (15 minutes)</i></li><li>• <b>Ensuring excellence of care for mitral regurgitation – Centers of excellence and physician competence</b> <i>Vinay Badhwar, MD, FACC (15 minutes)</i></li><li>• Interactive Table Discussion (60 minutes)</li><li>• Report Back to Full Group (30 minutes)</li></ul>
12:15pm	<b>LUNCH</b>
1:00pm	<b>Session 7: Panel Discussion – Investigation and Regulation of Novel Transcatheter Valve Technologies</b> <p><i>Moderator:</i></p> <ul style="list-style-type: none"><li>• <i>Joseph E. Bavaria, MD</i><p><i>Panelists:</i></p><ul style="list-style-type: none"><li>• <b>Evaluation and utilization of novel transcatheter valve technologies in the US and abroad</b> <i>David R. Holmes, Jr., MD, MACC (5 minutes)</i></li><li>• <b>Clinical trial strategies for new transcatheter valves</b> <i>Laura Mauri, MD, MSc, FACC (5 minutes)</i></li><li>• <b>National coverage for transcatheter valve technologies</b> <i>Jyme H. Schafer, MD, MPH (5 minutes)</i></li><li>• <b>FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US</b> <i>Nicole Ibrahim, PhD (5 minutes)</i></li><li>• Panel Q &amp; A (25 minutes)</li><li>• Interactive Table Discussion (45 minutes)</li><li>• Report Back to Full Group (30 minutes)</li></ul></li></ul>
3:00pm	<b>Recap of the Day and Next Steps</b>
3:30pm	<b>ADJOURN</b>